
PRESS RELEASE

Ypsomed newly supplies AstraZeneca with the Bydureon® Pen

Burgdorf, September 19, 2014, 07.00 h – The Burgdorf diabetes specialist Ypsomed can announce another success in the Injection Systems business segment: The British company AstraZeneca, one of the largest biopharmaceutical companies in the world, will use an Ypsomed injection system for subcutaneous administration of its diabetes drug Bydureon®.

Starting in the US from September 2014, the glucagon-like peptide-1 (GLP-1) receptor agonist exenatide will be administered with the dual-chamber injection system Bydureon® Pen, based on Ypsomed's LyoTwist® platform. AstraZeneca was granted the appropriate approval by the US FDA in February 2014. Bydureon® is injected weekly for the treatment of type 2 diabetes. It stimulates insulin production in the pancreas, reduces glucagon levels, and prevents significant increases in blood glucose levels. User-friendliness and a simple, sturdy design were key requirements for the injection system, which were convincingly implemented by Ypsomed. An important success factor is Ypsomed's 30 years of experience in the development and manufacture of injection systems, including devices specifically designed for dual-chamber cartridges. The injection system, which consists of only five parts, is manufactured in Switzerland. From 2015 Bydureon® will also be administered with Ypsomed's injection system outside the US.

"This new cooperation shows that the decision to invest in platforms for injection systems was correct. Based on the platform product the customer sees what the end product will look like and how it will operate. For the pharmaceutical partner the time to market and project risks are substantially reduced. Those are crucial success factors in this sector," says CEO Simon Michel, explaining the business success.

For further information, please contact Benjamin Overney, Head of Investor & Public Relations at Ypsomed Holding AG, at telephone number +41 34 424 41 59 or via e-mail (benjamin.overney@ypsomed.com).

About the Ypsomed Group

The Ypsomed Group is the leading developer and manufacturer of injection systems for self-medication and a renowned diabetes specialist with almost 30 years of experience. Founded in 2003 from the well-known company Disetronic Medical Systems, today it offers insulin pumps and injection systems as well as pen needles for the treatment of diabetes, growth disorders, infertility, oncology and other therapeutic areas. Ypsomed is regarded as a leader in innovation and technology and is the preferred partner of pharmaceutical and biotech companies in the self-medication field. Ypsomed has established itself with the umbrella brands mylife™ Diabetescare and YDS™ Ypsomed Delivery Systems in retailing and in business-to-business trading. Under the brand name mylife™ Diabetescare, Ypsomed offers patients an extensive range of self-manufactured products or commercial products for the treatment of diabetes. The range from YDS™ reflects the many years of experience and competence in the field of injection systems. With an innovative and patent-protected product portfolio of pen systems and autoinjectors, which can be adapted to customer requirements, and contract development and manufacturing, Ypsomed provides customer oriented product and service solutions to pharmaceutical and biotech companies worldwide.

Ypsomed has its headquarters in Burgdorf in Switzerland and owns several manufacturing sites in Switzerland and in the Czech Republic. Ypsomed has its own subsidiaries throughout Europe and works with leading, independent marketing partners worldwide. The Ypsomed Group has around 1,000 employees.